1999
DOI: 10.1046/j.1365-2036.1999.00599.x
|View full text |Cite
|
Sign up to set email alerts
|

Low molecular weight heparin as adjuvant therapy in active ulcerative colitis

Abstract: Background: Heparin given intravenously has shown beneficial effects in the treatment of refractory ulcerative colitis in open trials. Low molecular weight heparin (LMWH) offers advantages in the method of administration but have not been evaluated in inflammatory bowel disease conditions.Aim: To assess the tolerability and safety of subcutaneous self‐administered LMWH in outpatients with refractory ulcerative colitis and to evaluate any potential adjuvant therapeutic effect.Patients and Methods: Twelve patien… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
61
0
2

Year Published

2006
2006
2015
2015

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 99 publications
(65 citation statements)
references
References 15 publications
2
61
0
2
Order By: Relevance
“…However, whether exacerbated coagulation participates in the etiology of inflammatory bowel disease remains controversial. It is interesting to note that the risk of inflammatory bowel disease is lower than expected in patients with inherited bleeding disorders (10) and that several observational studies show a beneficial effect of anticoagulant treatment (11)(12)(13)(14). However, a randomized clinical trial did not confirm this beneficial effect of heparin treatment (15).…”
Section: Inflammatory Bowel Disease Patientsmentioning
confidence: 86%
See 2 more Smart Citations
“…However, whether exacerbated coagulation participates in the etiology of inflammatory bowel disease remains controversial. It is interesting to note that the risk of inflammatory bowel disease is lower than expected in patients with inherited bleeding disorders (10) and that several observational studies show a beneficial effect of anticoagulant treatment (11)(12)(13)(14). However, a randomized clinical trial did not confirm this beneficial effect of heparin treatment (15).…”
Section: Inflammatory Bowel Disease Patientsmentioning
confidence: 86%
“…Nine out of ten patients on combined heparin and sulfasalazine therapy became asymptomatic, D 1 7 ( 9 -1 0 ) 1 1 1 9 -1 1 2 whereas patient number 10 had a partial response (12). Nadroparine treatment alone significantly improved endoscopic and histological signs of inflammation in 20 out of 25 patients (11), whereas dalteparin treatment resulted in complete remission in 6 out of 12 patients (13). Although a small clinical randomized trial could not confirm these beneficial effects (15), the inclusion criteria of mainly mildly affected patients and the short duration of LMWH treatment did not allow confirmative conclusions.…”
Section: S E P T E M B E R -O C T O B E R 2 0 1 1 T I S S U E F a Cmentioning
confidence: 99%
See 1 more Smart Citation
“…For the expected proportion with specified outcome: p 1 ϭ improved on heparin 0.80 (based on previous uncontrolled studies [11][12][13] ), p 2 ϭ improved on placebo 0.20. The common SD was 0.68.…”
Section: Methodsmentioning
confidence: 99%
“…Three studies performed with low molecular weight heparin (LMWH) also showed benefit, with clinical improvement rates ranging from 58%-91%. [11][12][13] The treatment was well tolerated. None of these 3 studies, however, was controlled.…”
mentioning
confidence: 99%